Search Results for "Http Dx Doi Org 10 1002 Adma 201104290"

10:21 EDT 29th May 2015 | BioPortfolio

Matching Channels

Freiberg Infraction

Freiberg's disease is an osteochondrosis of the metatarsal head, most commonly occurring in young athletes older than 12 years who perform on their toes in either sprinting or jumping activities...

Pediculosis - louse (lice) treatment

   To view our most recent articles on Lice Treatment please go to:    

Pediculosis - louse (lice) infestation

   To view our most recent article on Lice Infestation please go to: 

Pediculosis - louse (lice) diagnosis

   To view our most recent articals on Lice Diagnosis please view:

G-protein-coupled receptors (GPCRs)

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers th...

Matching News

ADMA Biologics, Inc. (Nasdaq:ADMA) to Ring The Nasdaq Stock Market Opening Bell

ADVISORY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- What:  ADMA Biologics, Inc. (Nasdaq:ADMA), a biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based bio...

Esperion hits record high on ETC-1002 results

Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) jumped $22.50 (29%) to $99.60, hitting an all-time high on Tuesday after the company said ETC-1002 met the primary endpoint of lowering LDL-cholester...

ADMA Biologics nets $9.2mm via FOPO

Infectious disease-focused ADMA Biologics Inc. netted $9.2mm through the follow-on offering of 1.2mm common shares at $8 each. Proceeds will help fund the anticipated launch of its lead antibody candi...

ADMA Biologics nets $10.6mm via FOPO

Infectious disease-focused ADMA Biologics Inc. netted $10.6mm through the follow-on offering of 1.4mm common shares (including the overallotment) at $8 each. Proceeds will help fund the anticipated la...

ADMA’s lead product meets primary endpoint in Phase III trial

US-based biopharmaceutical company ADMA Biologics says that its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.

ADMA will submit BLA on Phase III RI-002 results

Ramsey, New Jersey-based ADMA Biologics will submit a biologics license application (BLA) to the US FDA during the first half of 2015 based on positive Phase III clinical trial results for RI-002 in t...

Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002 Added to Stable Statin Therapy in Patients With Hypercholesterolemia

ANN ARBOR, MI--(Marketwired - March 17, 2015) - Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-densit...

ADMA financial update

Matching PubMed Articles

First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia.

Placental growth factor (PGF), soluble fms-like tyrosine kinase 1 (sFLT1) and asymmetric dimethylarginine (ADMA) are involved in the pathogenesis of preeclampsia. Abnormal maternal sFLT1, PGF and ADMA...

Physical exercise reduces synthesis of ADMA, SDMA, and L-Arg.

Increased levels of asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and low plasma level of L-arginine (L-ARG) are all conditions likely to decrease nitric oxide (NO) production....

Endothelial DDAH1 is an Important Regulator of Angiogenesis but Does Not Regulate Vascular Reactivity or Hemodynamic Homeostasis.

-Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthesis and a risk factor for cardiovascular disease. Dimethylarginine dimethylaminohydrolase (DDAH) enzymes are respon...

Enhance Cancer Cell Recognition and Overcome Drug Resistance Using Hyaluronic Acid and α-Tocopheryl Succinate Based Multifunctional Nanoparticles.

Multidrug resistance (MDR) presents a clinical obstacle to cancer chemotherapy. The main purpose of this study was to evaluate the potential of a hyaluronic acid (HA) and α-tocopheryl succinate (α-T...

Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage.

Nitric oxide (NO) production is diminished in many patients with cardiovascular and renal disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, and elevated plasma le...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement